AbCellera Biologics Inc. is a biotechnology company based in Vancouver, Canada, focused on discovering and developing therapeutic antibodies. The company operates a technology-driven antibody discovery platform that integrates biology, computation, and engineering to identify drug candidates from natural immune responses for a wide range of diseases. AbCellera’s platform searches, decodes, and analyzes immune systems at scale, aiming to generate high-quality antibody leads that can be advanced into clinical development by AbCellera or its partners. It collaborates with pharmaceutical and biotechnology companies to create antibody-based medicines across multiple indications and modalities, including complex and hard-to-drug targets. Founded in 2012 and headquartered in Vancouver, British Columbia, AbCellera Biologics Inc. plays a specialized role in the biopharmaceutical ecosystem as an innovation partner, providing discovery capabilities that support the development of new antibody therapeutics for global healthcare markets.